Streetbeat News

Revenues

DNUT

Krispy Kreme has projected its FY24 adjusted diluted EPS to be between $0.27 and $0.31, below the $0.38 estimate. The company expects net revenue growth of 5%-7% and adjusted EBITDA growth of 8%-11% for FY24. Additionally, Krispy Kreme is exploring strategic alternatives for Insomnia Cookies, with the FY24 guidance including operations from Insomnia Cookies.

Portfolio Pulse from Benzinga Newsdesk

February 13, 2024 | 12:23 pm

MCO

Moody's Corporation (MCO) has provided its full year 2024 guidance, forecasting revenue growth in the high-single-digit to low-double-digit percent range and an adjusted EPS of $10.25-$11.00, which is below the estimated $11.15. The guidance also includes details on operating expenses, margins, interest expense, tax rate, cash flow, and share repurchases. Moody's Analytics expects a 10% revenue increase and Moody's Investors Service anticipates revenue growth in the high-single-digit to low-double-digit percent range.

Portfolio Pulse from Benzinga Newsdesk

February 13, 2024 | 12:19 pm

BRKR

Bruker Corporation has updated its FY23 revenue outlook to $2.88B-$2.91B, slightly below the $2.92B estimate but higher than its previous forecast of $2.85B-$2.90B. The company also projects its FY23 adjusted EPS to be $2.48-$2.53, which is below the $2.55 estimate. Additionally, Bruker anticipates organic revenue growth of 11.5%-12.5%, a 150 basis points increase from its prior outlook.

Portfolio Pulse from Benzinga Newsdesk

February 13, 2024 | 12:17 pm

AKTS

Akoustis expects to achieve record revenue in Q3, forecasting an 18-25% increase sequentially. CEO Jeff Shealy emphasized the company's focus on product cost savings and expense reductions.

Portfolio Pulse from Benzinga Newsdesk

February 13, 2024 | 12:16 pm

LCII

LCI Industries reported January 2024 consolidated net sales of approximately $308 million, marking a 13% increase from January 2023. This growth is attributed mainly to a 57% rise in North American RV production, despite a 44% drop in marine sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

February 13, 2024 | 12:15 pm

BIIB

Biogen anticipates a decline in total revenue by a low- to mid-single digit percentage in 2024 compared to 2023, while expecting core pharmaceutical revenue (product revenue plus Leqembi) to remain flat versus 2023. The company also forecasts a low-double digit percentage growth in operating income for 2024, alongside a mid-single digit percentage point expansion in operating margin.

Portfolio Pulse from Benzinga Newsdesk

February 13, 2024 | 12:14 pm

ZTS

Zoetis projects its 2024 revenue to be between $9.075 billion and $9.225 billion, indicating an operational growth of 7% to 9%, compared to the consensus estimate of $9.21 billion.

Portfolio Pulse from Benzinga Newsdesk

February 13, 2024 | 12:05 pm

DDOG

Datadog has provided its Q1 and FY24 financial outlook, expecting Q1 revenue of $587M-$591M, slightly above estimates, but with an adjusted EPS of $0.33-$0.35, below the $0.39 estimate. For FY24, the company forecasts revenue of $2.555B-$2.575B, slightly below the $2.59B estimate, and an adjusted EPS of $1.38-$1.44, significantly lower than the $1.83 estimate.

Portfolio Pulse from Benzinga Newsdesk

February 13, 2024 | 12:05 pm

ENOV

Analysts have diverse opinions on Enovis (NYSE:ENOV), with recent ratings ranging from bullish to bearish. Over the last three months, 5 analysts have updated their views, showing a shift towards more bullish sentiments. The average 12-month price target is now $72.2, up from $65.67, indicating a 9.94% increase. Enovis, a medical technology company, has shown positive revenue growth and strong financial health indicators despite a lower market capitalization compared to industry peers.

Portfolio Pulse from Benzinga Insights

February 13, 2024 | 12:01 pm

EPRT

Essential Props Realty (NYSE:EPRT) has been evaluated by 6 analysts over the last three months, showing a shift towards a more bullish outlook. The average 12-month price target for EPRT has been raised to $28.08, indicating a 5.64% increase from the previous target. The company's financial performance is strong, with significant revenue growth, high net margin, and exceptional ROE and ROA, surpassing industry averages. This positive financial outlook, combined with the recent analyst upgrades, suggests a favorable short-term impact on EPRT's stock price.

Portfolio Pulse from Benzinga Insights

February 13, 2024 | 12:00 pm